LRRC8A inhibitors belong to a class of chemical compounds that specifically target and modulate the function of leucine-rich repeat-containing 8A (LRRC8A) protein. LRRC8A is a critical component of the volume-regulated anion channels (VRACs), which play a pivotal role in cellular homeostasis by regulating cell volume and ion balance. These inhibitors interact with LRRC8A to disrupt or alter its normal physiological activity, thereby influencing the function of VRACs.
The LRRC8A protein is an essential subunit of the heteromeric VRAC complex, contributing to its assembly and proper functioning. VRACs are involved in various cellular processes, such as cell volume regulation, cell migration, and apoptosis. LRRC8A inhibitors may exert their effects by binding to specific sites on the LRRC8A protein, thereby modulating the opening and closing of VRACs. This modulation can lead to alterations in ion transport across the cell membrane, impacting the overall cellular homeostasis. Understanding the precise mechanism of action of LRRC8A inhibitors is crucial for unraveling their potential applications in various research areas, although any such implications are beyond the scope of this description. The development and study of LRRC8A inhibitors contribute to the expanding knowledge of cellular physiology and may offer insights into the intricate regulatory mechanisms governing ion channels and cell volume dynamics.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Tamoxifen | 10540-29-1 | sc-208414 | 2.5 g | $272.00 | 18 | |
A known modulator of several ion channels and can inhibit LRRC8A-containing VRACs by altering their regulation and conductivity. | ||||||
Phloretin | 60-82-2 | sc-3548 sc-3548A | 200 mg 1 g | $64.00 $255.00 | 13 | |
A dihydrochalcone that can inhibit chloride channels, potentially affecting LRRC8A function by reducing the chloride currents mediated by VRACs. | ||||||
5-Nitro-2-(3-phenylpropylamino)benzoic Acid (NPPB) | 107254-86-4 | sc-201542 sc-201542B sc-201542A | 10 mg 25 mg 50 mg | $109.00 $193.00 $317.00 | 7 | |
A broad-spectrum chloride channel blocker that can inhibit LRRC8A by decreasing its chloride conduction capability within VRACs. | ||||||
Flufenamic acid | 530-78-9 | sc-205699 sc-205699A sc-205699B sc-205699C | 10 g 50 g 100 g 250 g | $27.00 $79.00 $154.00 $309.00 | 1 | |
A nonsteroidal anti-inflammatory drug that can inhibit various ion channels, potentially affecting LRRC8A activity within VRACs. | ||||||
DIDS, Disodium Salt | 67483-13-0 | sc-203919A sc-203919B sc-203919 sc-203919C | 25 mg 100 mg 250 mg 1 g | $51.00 $163.00 $286.00 $683.00 | 6 | |
An anion transport inhibitor that can affect LRRC8A by blocking anion exchange and related chloride channel activities. | ||||||
Verapamil | 52-53-9 | sc-507373 | 1 g | $374.00 | ||
A calcium channel blocker which can indirectly affect LRRC8A function by modulating cellular calcium levels, potentially influencing VRAC activity. | ||||||
Glyburide (Glibenclamide) | 10238-21-8 | sc-200982 sc-200982A sc-200982D sc-200982B sc-200982C | 1 g 5 g 25 g 100 g 500 g | $46.00 $61.00 $117.00 $173.00 $530.00 | 36 | |
An ATP-sensitive potassium channel inhibitor that may also inhibit VRACs, potentially affecting the LRRC8A component. | ||||||
Carbenoxolone | 5697-56-3 | sc-507294 | 1 g | $50.00 | ||
A gap junction blocker that can inhibit connexin hemichannels and potentially influence LRRC8A activity by modifying intracellular signaling pathways. | ||||||